A Phase 2 Study to Evaluate Efficacy of Calaspargase Pegol-mknl and Decitabine Combined With Venetoclax in Pediatric, Adolescent, and Young Adult Patients With Relapsed/Refractory T-cell Acute Lymphoblastic Leukemia (T-ALL) and T- Cell Lymphoblastic Lymphoma (T-LLy)
Phase 2
Not yet recruiting
- Conditions
- T-cell Acute Lymphoblastic LeukemiaT-Cell Lymphoblastic Lymphoma
- Interventions
- First Posted Date
- 2024-08-19
- Last Posted Date
- 2025-04-09
- Lead Sponsor
- M.D. Anderson Cancer Center
- Target Recruit Count
- 22
- Registration Number
- NCT06561074
- Locations
- 🇺🇸
MD Anderson Cancer Center, Houston, Texas, United States
CTX-009 With Gemcitabine, Cisplatin, and Durvalumab as First-line Therapy in Patients With Unresectable or Metastatic Biliary Tract Cancers
Phase 1
Recruiting
- Conditions
- Metastatic Biliary Tract Cancer
- Interventions
- First Posted Date
- 2024-08-12
- Last Posted Date
- 2025-04-18
- Lead Sponsor
- M.D. Anderson Cancer Center
- Target Recruit Count
- 50
- Registration Number
- NCT06548412
- Locations
- 🇺🇸
MD Anderson Cancer Center, Houston, Texas, United States
Neoadjuvant Immune Checkpoint Blockade + a Prebiotic Food-enriched Dietary Intervention to Optimize Immune Response in Melanoma: NEO-PreFED
Phase 2
Recruiting
- Conditions
- Melanoma
- Interventions
- Dietary Supplement: Prebiotic Xnack Packouts
- First Posted Date
- 2024-08-12
- Last Posted Date
- 2025-04-09
- Lead Sponsor
- M.D. Anderson Cancer Center
- Target Recruit Count
- 35
- Registration Number
- NCT06548789
- Locations
- 🇺🇸
MD Anderson Cancer Center, Houston, Texas, United States
Clinical and Molecular Features of Oral Premalignancy and Oral Cancer
Recruiting
- Conditions
- Oral Cancer
- Interventions
- Behavioral: Radiation
- First Posted Date
- 2024-08-12
- Last Posted Date
- 2025-05-01
- Lead Sponsor
- M.D. Anderson Cancer Center
- Target Recruit Count
- 1000
- Registration Number
- NCT06550050
- Locations
- 🇺🇸
MD Anderson Cancer Center, Houston, Texas, United States
Establishing Daily Applicable Parameters for Using Magnetic Resonance Spectroscopy of Spinal Cord
Not Applicable
Recruiting
- Conditions
- Spinal Cord
- Interventions
- Diagnostic Test: Magnetic Resonance Spectroscopy (MRS) Scan
- First Posted Date
- 2024-08-12
- Last Posted Date
- 2025-03-30
- Lead Sponsor
- M.D. Anderson Cancer Center
- Target Recruit Count
- 13
- Registration Number
- NCT06548776
- Locations
- 🇺🇸
MD Anderson Cancer Center, Houston, Texas, United States
18F-FSPG PET/CT as a Non-Invasive Imaging Biomarker for Treatment Response to Chemoradiation in Esophageal Cancer
Recruiting
- Conditions
- Esophageal Carcinoma
- Interventions
- Other: Non-Interventional Study
- First Posted Date
- 2024-08-12
- Last Posted Date
- 2025-04-09
- Lead Sponsor
- M.D. Anderson Cancer Center
- Target Recruit Count
- 60
- Registration Number
- NCT06549413
- Locations
- 🇺🇸
M D Anderson Cancer Center, Houston, Texas, United States
A Phase 1B/2A Trial of NADUNOLIMAB in Combination With Azacitidine (With/Without Venetoclax) in Patients With Myelodysplastic Syndrome (MDS) and Acute Myelogenous Leukemia (AML)
Phase 1
Not yet recruiting
- Conditions
- Myelodysplastic Syndrome(MDS)Acute Myelogenous Leukemia (AML)
- Interventions
- First Posted Date
- 2024-08-12
- Last Posted Date
- 2024-11-25
- Lead Sponsor
- M.D. Anderson Cancer Center
- Target Recruit Count
- 40
- Registration Number
- NCT06548230
- Locations
- 🇺🇸
MD Anderson Cancer Center, Houston, Texas, United States
ACT-Together (Acting on Cancer Testing-Together)
Not Applicable
Recruiting
- Conditions
- Cancer
- Interventions
- Other: Focus GroupOther: Education Content
- First Posted Date
- 2024-08-12
- Last Posted Date
- 2025-04-02
- Lead Sponsor
- M.D. Anderson Cancer Center
- Target Recruit Count
- 15
- Registration Number
- NCT06549153
- Locations
- 🇺🇸
MD Anderson Cancer Center, Houston, Texas, United States
Phase Ib Study of AlpeliSib With PEmbroLizumab in Patients With mEtastatic Breast caNcer or melanomA (SELENA)
Phase 1
Recruiting
- Conditions
- Acute Myelogenous Leukemia (AML)Myelodysplastic Syndrome(MDS)
- Interventions
- First Posted Date
- 2024-08-09
- Last Posted Date
- 2025-03-17
- Lead Sponsor
- M.D. Anderson Cancer Center
- Target Recruit Count
- 50
- Registration Number
- NCT06545682
- Locations
- 🇺🇸
MD Anderson Cancer Center, Houston, Texas, United States
Comprehensive Yoga Therapy Based Lifestyle Prehabilitation Program for Women With Ovarian Cancer
Not Applicable
Not yet recruiting
- Conditions
- Ovarian Cancer
- Interventions
- Other: Yoga Therapy for Nutritional, Physical, and Psychosocial Prehabilitation
- First Posted Date
- 2024-08-09
- Last Posted Date
- 2024-08-09
- Lead Sponsor
- M.D. Anderson Cancer Center
- Target Recruit Count
- 44
- Registration Number
- NCT06545604
- Locations
- 🇺🇸
MD Anderson Cancer Center, Houston, Texas, United States
© Copyright 2025. All Rights Reserved by MedPath